The consequences of drug misuse on post-marketing surveillance
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Over the past decade, the ‘traditional’ drug scenario has shown significant changes because of the emergence of a range of molecules, e.g. the novel psychoactive substances (NPS), which are either ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Second, the occurrence of a persistent post-withdrawal disorder is only occasionally observed with both antipsychotics (e.g.tardive dyskinesia and supersensitivity psychosis) and ADs (e.g.mood fluctuations; 16).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“This may well be the case with both antidepressants (ADs; 14-16) and benzodiazepines (BDZ; 17).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [16]
In the citing paper
“Quetiapine psychotropic effects are associated with both increased levels of DA in the nucleus accumbens (NAc) area (48) and D2 receptor blockade, although norquetiapine-related NA reuptake blockade; 5-HT7 antagonist properties; and sigma receptor activation; may contribute to its misuse liability (for a review, see 16).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 41 · Cited by 21
Research works printed but not linked: 5
- World Health Organization (WHO). 34th meeting of the WHO Expert Committee on Drug Dependence (ECDD); 2006 Mar 28-31; Geneva, Switzerland.
- Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015;54:202-212. · DOI · Paper page
- Bogart GT, Ott CA. Abuse of second-generation antipsychotics: what prescribers need to know. Curr Psychiatr. 2011;10(5). [cited 2016 Mar 2]. Available from: http://www.currentpsychiatry.com/ index.php?id=22661&tx_ttnews[tt_news]=176014
- Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118-122. · DOI · Paper page
- Canadian Agency for Drugs and Technologies in Health (CADTH). Abuse and misuse potential of pregabalin: a review of the clinical evidence; Context and policy issues; 2012 [cited 2016 Mar 7]. Available from: http://dpic.org/sites/default/files/PregabalinAbuse_ CADTH_24Apr2012.pdf
Metadata
- Authors
- Schifano, F., Papanti, G. D., Orsolini, L., & Corkery, J. M.
- Affiliations
- University of Hertfordshire (GB)
- Corresponding author
- Schifano, Fabrizio
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-04-25
- Volume
- 9
- Issue
- 7
- Pages
- 867-871
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2341524139
- Cited by
- 21
- References
- 41
- Citations by year
- 2025: 2 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Funders
- European Commission (Drug Prevention and Information Programme 2014–16;)
- EU Commission (JUST/2013/ISEC/DRUGS/AG/6429) Project EPS/NPS (Enh)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- drug abuse, post-marketing surveillance, new psychoactive substances, drug safety, adverse drug reactions, drug regulation
- MeSH terms
- Humans, Product Surveillance, Postmarketing, Psychotropic Drugs, Substance-Related Disorders, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The consequences of drug misuse on post-marketing surveillance. https://app.cochat.ai/papers/10.1080/17512433.2016.1178571
- The paper
- Schifano, F., Papanti, G. D., Orsolini, L., & Corkery, J. M. (2016). The consequences of drug misuse on post-marketing surveillance. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2016.1178571
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.